Anyone who decides to take an HIV drug for anti aging better hide the bottle whenever a woman (or man) comes over. Imagine having to explain that one 
4 Likes
They are living a lot longer it seems (even longer than we straight males).
But, It’s probably extremely difficult to parse out the data to distinguish between people living longer because they are HIV positive but not getting full blown AIDs (due to all the different drugs that have come on the market), vs. taking the drug prophetically, vs. other confounding factors…
2 Likes
Striking chart. Straight up from 1995. That must be when HIV drugs came on the market.
Of course, the biggest issue with this paper is that we don’t see any functional measures and benefits.
So - I thought I’d dig deeper into this paper and related evidence:
Prompt:
Given the mechanisms of actions highlighted in this paper for FTC/TAF (Descovy), what would be any potential, hypothetical functional benefits that might be seen in humans given the significant reductions in biological aging clocks?
Google Gemini 3 Pro / Thinking Mode:
Based on the mechanisms of action and the system-specific biological aging clock reductions identified in the Anderson et al. (2026) paper, the following hypothetical functional benefits can be extrapolated. These benefits are centered on the suppression of the retrotransposon-inflammation axis and the subsequent reduction in systemic inflammatory tone .
1. Restoration of Immunological Resilience
The study observed a significant shift in immune cell composition, specifically an increase in the proportion of naive CD4+ T cells and regulatory T cells (Tregs), alongside a decrease in neutrophils .
-
Hypothetical Benefit: In older populations, the depletion of the naive T-cell pool is a primary driver of immune senescence, leading to poor vaccine responses and increased susceptibility to novel pathogens . A pharmacological intervention that restores these pools could theoretically enhance immunological “youthfulness” and defense capabilities.
-
Inflammatory Control: The increase in Tregs combined with reduced neutrophils suggests a shift toward a more immunoregulatory and less pro-inflammatory environment . This may reduce the chronic “bystander” tissue damage caused by hyper-active innate immune responses.
2. Neuroprotection and Cognitive Maintenance
The analysis demonstrated a significant reduction in Systems Brain Age (-2.18 years, p=0.039).
-
Hypothetical Benefit: Broader research into reverse transcriptase inhibitors (like 3TC) has shown protection against age-related cognitive dysfunction in animal models by suppressing brain-specific inflammatory signatures .
-
Mechanism: In humans, suppressing LINE-1-triggered type I interferon signaling in the central nervous system could mitigate neuroinflammation, which is a proximal driver of neurodegenerative decline and cognitive impairment .
3. Cardiovascular and Metabolic Optimization
The FTC/TAF group showed robust reductions in Systems Heart Age (-3.23 years, p=0.009) and Systems Metabolic Age (-3.38 years, p=0.005) .
- Hypothetical Benefit: These epigenetic shifts may correlate with improved arterial function and enhanced metabolic flexibility.
- Inflammatory Proxies: The study identified a significant reduction in DNAm-derived IL-6 levels . Because IL-6 is a key driver of atherosclerotic plaque progression and insulin resistance, suppressing its signaling through retrotransposon inhibition could theoretically delay the onset of cardiovascular disease and metabolic syndrome .
4. Slowing the Pace of Biological Decay
The DunedinPACE clock, which measures the “speed” of aging, showed a significant reduction of 0.061.
- Hypothetical Benefit: A roughly 6% reduction in the pace of aging, if sustained, could theoretically delay the simultaneous onset of multiple age-related chronic diseases (the Geroscience Hypothesis).
- Systemic Resilience: The 6.33-year reduction in the PhenoAge clock suggests an improvement in the body’s ability to maintain homeostasis under stress.
Critical Analysis and Knowledge Gaps
While the mechanistic data is compelling, several factors limit the immediate translation of these findings into clinical practice:
-
Cohort Age Bias: This study used healthy adults with a mean age of approximately 28 years. It remains unproven whether the same magnitude of effect—or any effect at all—would occur in older adults whose silencing mechanisms for transposable elements are more severely degraded.
-
Absence of Functional Testing: The trial relied entirely on molecular biomarkers (epigenetic clocks) . There was no direct measurement of physical strength, cognitive speed, or organ function to verify that “younger” clocks result in improved physical performance.
-
Exploratory Status: As a post-hoc analysis of studies not originally designed for aging, the results were not corrected for multiple testing . Consequently, these benefits should be viewed as informed speculation that requires validation in prospective, placebo-controlled trials .
1 Like